Citations

Clear

367 citation(s) found for "Benson, Al".

Metal-binding properties of human centrin-2 determined by micro-electrospray ionization mass spectrometry and UV spectroscopy
Craig, Theodore A., Benson, Linda M., Bergen, H. Robert, Venyaminov, S.Yu., Salisbury, Jeffrey L., Ryan, Zachary C. , Thompson, James R. , Sperry, Justin B. , Gross, Michael L. , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Journal of the American Society for Mass Spectrometry | June 7, 2006 | Volume: 17 | Issue: 8 | Pages: 1158-1171

10.1016/j.jasms.2006.04.029 | PMID 16750384 Get It

The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes
Walker, Denise L., Miller, Jennifer, Benson, Linda M., Tomlinson, Andrew J., Naylor, Stephen , Blajeski, April L., LoRusso, Patricia , Ames, Matthew M. , Reid, Joel M.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 4 | Pages: 1471-1480

10.1158/1078-0432.ccr-0557-03 | PMID 14977851 Get It

Abstract Pyrazoloacridine (PZA) is an experimental antitumor agent presently under investigation for treatment of solid tumors on the basis of its unique mechanism of action and selectivity for human solid tumor xenograft in mice. Using capillary electrophoresis coupled with electrospray ionization mass spectrometry, we have identified three oxidative PZA metabolites, 9-desmethyl-PZA, N-demethyl-PZA, and PZA N-oxide. The cytochrome P450 (CYP) isoforms involved in PZA metabolism were characterized by studies with CYP chemical inhibitors, correlation of marker activities for selected CYPs with formation of the metabolites using a human liver panel, and PZA metabolism by cDNA-expressed CYPs. 9-Desmethyl-PZA formation was catalyzed by CYP1A2, whereas N-demethyl-PZA formation was catalyzed by CYP3A4. PZA N-oxide formation was catalyzed by flavin monooxygenase (FMO) rather than CYP, as determined by studies with chemical inhibitors of FMO and metabolism by cDNA-expressed human flavin monooxygenase. After administration of [10b-14C]PZA to mice, six urinary metabolites were detected by high-performance liquid chromatography UV and radiochromatograms including 9-desmethyl-PZA, N-demethyl-PZA, and PZA N-oxide. Trace concentrations of 9-desmethyl-PZA and PZA N-oxide were detected in mouse plasma. PZA N-oxide and N-demethyl-PZA were detected in urine from patients after PZA administration. PZA, 9-desmethyl-PZA, and PZA N-oxide inhibited growth of A375 human melanoma cells. IC50 values were 0.17, 0.11, and 7.0 μm, respectively, for the three molecules.
Evaluation of the DNA Binding Tendencies of the Transition State Regulator AbrB
Bobay, Benjamin G. , Benson, Linda M., Naylor, Stephen , Feeney, Brett, Goshe, Michael B. , Strauch, Mark A., Thompson, Richele J., Cavanagh, John , Clark, A. Clay

Mayo Clinic

Biochemistry | December 21, 2004 | Volume: 43 | Issue: 51 | Pages: 16106-16118

10.1021/bi048399h | PMID 15610005 Get It

Impact of therapeutic endoscopy on the treatment of bleeding duodenal ulcers: 1980–1990
Miller, Alexander R., Farnell, Michael B., Kelly, Keith A., Gostout, Christopher J., Benson, Joanne T.

Mayo Clinic

World Journal of Surgery | December 10, 2004 | Volume: 19 | Issue: 1 | Pages: 89-94

10.1007/bf00316985 | PMID 7740816 Get It

AbstractTherapeutic endoscopy (TE) has provided a new means for treating peptic ulcer disease, prompting a reevaluation of surgery's role. The aim of this study was to determine if surgical therapy of bleeding duodenal ulcers has changed since the advent of TE. This retrospective review involved consecutive time periods during which TE was (1985–1990) and was not (1980–1984) widely available. Exclusion criteria were prior gastric surgery, nonpeptic conditions, and untreated ulcers. Inclusion standards were met by 252 patients (180 men, 72 women) whose mean age was 67 years. Patients were grouped by the initial therapeutic intervention. Groups were similar in age, medical condition (mean APACHE II score 16), and morbidity. Seventy‐five patients had surgery alone during 1980–1984 and 38 during 1985–1990. TE was initially performed on 134 patients during 1985–1990. Bleeding (n=30) and perforation (n=1) prompted emergent operation in 23% of cases following TE. Thus 69 (38+31) patients underwent surgery between 1985 and 1990. Preprocedure transfusions averaged 4.1 units in the endoscopic group and 8.2 units in the operative groups (p<0.0001). Disagreement existed between the endoscopic and surgical descriptions of ulcer location in 53% of cases. Emergent surgery was required in 45% of hemodynamically unstable patients versus 14% of stable patients who initially underwent TE (p<0.0001). Sixty‐one percent of incompletely visualized TE‐treated lesions required operation, and 18% of well visualized ulcers underwent operation (p<0.0001). Hospital mortality was similar (8% versus 16%) in the endoscopic and operated groups (p=0.7). Mean follow‐up was 540 days. The number of operations performed for bleeding duodenal ulcer did not change significantly during the TE era, and a significant subset (23%) of endoscopically treated patients required surgical therapy. TE failure was portended by hemodynamic instability or incomplete endoscopic visualization.
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Benson, Al B. , Catalano, Robert B., Engelking, Constance, Martenson, James A., McCallum, Richard W. , Mitchell, Edith P. , O’Dorisio, Thomas M. , Wadler, Scott, Ajani, Jaffer A. , Kornblau, Steven M. , Vokes, Everett E.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2004 | Volume: 22 | Issue: 14 | Pages: 2918-2926

10.1200/jco.2004.04.132 | PMID 15254061 Get It

Purpose To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. Methods An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines previously published by this group in the Journal of Clinical Oncology in 1998. MEDLINE searches were performed and the relevant literature published since 1998 was reviewed by all panel members. The treatment recommendations and algorithm were revised by panel consensus. Results A recent review of early toxic deaths occurring in two National Cancer Institute-sponsored cooperative group trials of irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the recognition of a life-threatening gastrointestinal syndrome and highlighted the need for vigilant monitoring and aggressive therapy for this serious complication. Loperamide remains the standard therapy for uncomplicated cases. However, the revised guidelines reflect the need for recognition of the early warning signs of complicated cases of diarrhea and the need for early and aggressive management, including the addition of antibiotics. Management of radiation-induced diarrhea is similar but may not require hospitalization, and chronic low- to intermediate-grade symptoms can be managed with continued loperamide. Conclusion With vigilant monitoring and aggressive therapy for cancer treatment-induced diarrhea, particularly in patients with early warning signs of severe complications, morbidity and mortality may be reduced.
Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130
Martenson, James A., Willett, Christopher G. , Sargent, Daniel J. , Mailliard, James A., Donohue, John H., Gunderson, Leonard L., Thomas, Charles R., Fisher, Barbara, Benson, Al B. , Myerson, Robert J., Goldberg, Richard M. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | July 13, 2004 | Volume: 22 | Issue: 16 | Pages: 3277-3283

10.1200/jco.2004.01.029 | PMID 15249584 Get It

Purpose Some patients with colon cancer have a high risk of local recurrence postoperatively. This trial was undertaken to determine whether radiation therapy added to an adjuvant chemotherapy regimen improves outcome in high-risk patients. Patients and Methods Patients with resected colon cancer with tumor adherence or invasion of surrounding structures, or with T3N1 or T3N2 tumors of the ascending or descending colon were randomly assigned to receive fluorouracil and levamisole therapy with or without radiation therapy. Patients who received chemotherapy and radiation therapy (chemoRT) received 45 to 50.4 Gy in 25 to 28 fractions beginning 28 days after starting chemotherapy. Patient enrollment was terminated because of slow accrual after 222 patients enrolled (original goal was 700 patients); 187 patients were assessable. Results Overall 5-year survival was 62% for chemotherapy patients and 58% for chemoRT patients (P > .50); 5-year disease-free survival was 51% for both groups (P > .50). Toxicity (≥ grade 3) occurred in 42% of chemotherapy patients and 54% of chemoRT patients (P = .04). Leukopenia (≥ grade 3) occurred in 10% of chemotherapy patients and 22% of chemoRT patients (P = .02). No significant difference in nonhematologic toxicity (≥ grade 3) was observed between chemoRT and chemotherapy patients (35% v 44%; P = .26). Conclusion Patients who received chemotherapy or chemoRT had similar overall survival and disease-free survival. Toxicity was higher among chemoRT patients. These results must be interpreted with caution because of the high number of ineligible patients and the limited power of the study to detect potentially meaningful differences.
In-Line Desalting Mass Spectrometry for the Study of Noncovalent Biological Complexes
Cavanagh, John , Benson, Linda M., Thompson, Richele J., Naylor, Stephen

Mayo Clinic

Analytical Chemistry | July 14, 2003 | Volume: 75 | Issue: 14 | Pages: 3281-3286

10.1021/ac030182q | PMID 14570174 Get It

Advantages of Thermococcus kodakaraenis (KOD) DNA Polymerase for PCR-mass spectrometry based analyses
Benson, Linda M., Null, Allison P., Muddiman, David C.

Mayo Clinic

Journal of the American Society for Mass Spectrometry | April 30, 2003 | Volume: 14 | Issue: 6 | Pages: 601-604

10.1016/s1044-0305(03)00148-x | PMID 12781461 Get It

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
Hamid, Oday , Varterasian, Mary , Wadler, Scott, Hecht, J. Randolph, Benson, Al B. , Uprichard, M. J., Omer, Charles, Bycott, Paul, Hackman, Robert C., Shields, Anthony F. , Galanis, Evanthia

Mayo Clinic

Journal of Clinical Oncology | April 15, 2003 | Volume: 21 | Issue: 8 | Pages: 1498-1504

10.1200/jco.2003.09.114 | PMID 12697873 Get It

Purpose: To evaluate the antitumor activity, safety, immune response, and replication of CI-1042 (ONYX-015), an E1B 55-kd gene-deleted replication-selective adenovirus, administered intravenously to patients with metastatic colorectal cancer Patients and Methods: Eighteen patients with metastatic colorectal cancer for whom prior chemotherapy failed were enrolled onto an open-label, multicenter, phase II study. CI-1042 was administered intravenously at a dose of 2 × 1012 viral particles every 2 weeks. Patients were evaluated for tumor response and toxicity; in addition, blood samples were taken for adenovirus DNA and neutralizing antibody analysis. Results: Common toxicities included flu-like symptoms, nausea, and emesis. All 18 patients eventually were removed from study because of progressive disease. Seven patients were assessed as having stable disease after 2 months of treatment, whereas two patients were considered to have stable disease after 4 months. Detectable circulating CI-1042 DNA was identified in 36% of patients 72 hours after last infusion, which is suggestive of ongoing viral replication. Conclusion: In this phase II study, intravenous CI-1042 was administered safely to patients with advanced colorectal cancer. Toxicity was manageable, consisting primarily of flu-like symptoms. Stable disease was experienced by seven patients for 11 to 18 weeks.
Formation of a Stable Cyano-Bridged Dinuclear Iron Cluster Following Oxidation of the Superoxide Reductases fromTreponemapallidumandDesulfovibriovulgariswith K3Fe(CN)6
Auchère, Françoise , Raleiras, Patrícia , Benson, Linda M., Venyaminov, S.Yu., Tavares, Pedro , Moura, José J. G. , Moura, Isabel , Rusnak, Frank

Mayo Clinic

Inorganic Chemistry | February 17, 2003 | Volume: 42 | Issue: 4 | Pages: 938-940

10.1021/ic0262886 | PMID 12588121 Get It